Bakri Y N, Given F T
Am J Obstet Gynecol. 1984 Sep 15;150(2):184-8. doi: 10.1016/s0002-9378(84)80014-9.
Systemic distribution of radioactive colloidal chromic phosphate P 32 after intraperitoneal instillation was studied in 10 patients with ovarian or endometrial malignancies. Seven patients without ascites received chromic phosphate P 32 for positive peritoneal washings, rupture of the capsule of the cyst during operation, or minimal Stage III disease. Three patients received chromic phosphate P 32 for recurrent ascites after multiple abdominal paracenteses. Blood and urine radioactivity measurements were performed at selected intervals. There was a clear statistically significant difference (p less than 0.01) between chromic phosphate P 32 activity levels in whole blood, red blood cells, and plasma in patients with and without ascites.
对10例卵巢或子宫内膜恶性肿瘤患者进行了研究，观察腹腔内注入放射性胶体磷酸铬P 32后的全身分布情况。7例无腹水的患者因腹腔冲洗液阳性、手术中囊肿包膜破裂或微小Ⅲ期疾病接受了磷酸铬P 32治疗。3例患者因多次腹腔穿刺后反复出现腹水而接受了磷酸铬P 32治疗。在选定的时间间隔进行血液和尿液放射性测量。有腹水和无腹水患者的全血、红细胞和血浆中磷酸铬P 32活性水平存在明显的统计学显著差异（p小于0.01）。
